This pre-competitive X-Species consortium, organized and led by InSphero, aims to bring together representatives from pharmaceutical companies engaged and investing in the development of cross-species drug testing and validation strategy for rapid, reliable drug-induced liver injury (DILI) screening and prediction.
Together we evaluate methods for recapitulating DILI-specific in vivo effects observed in animal models and patients using in vitro human and animal liver spheroid models and a comprehensive DILI compound library.
Results will be submitted for publication in a high-profile scientific journal and for consideration as a special interest group topic at the upcoming Society of Toxicology annual meeting.
